Development and Validation of an <i>In Silico</i> Decision Tool To Guide Optimization of Intravenous Artesunate Dosing Regimens for Severe Falciparum Malaria Patients — Sophie Zaloumis (2021) | RDL Network
Development and Validation of an <i>In Silico</i> Decision Tool To Guide Optimization of Intravenous Artesunate Dosing Regimens for Severe Falciparum Malaria Patients
Antimicrobial Agents and Chemotherapy 65(6)
Article 2021 English
Authors
SZ
Sophie Zaloumis
JW
Jason M. Whyte
JT
Joel Tärning
Abstract
1 min read
Most deaths from severe falciparum malaria occur within 24 h of presentation to a hospital. Intravenous (i.v.) artesunate is the first-line treatment for severe falciparum malaria, but its efficacy may be compromised by delayed parasitological responses.
Tran Tinh Hien, Nguyen Hoan Phu, Nguyen Thi Hoang, Tran Thi Hong Chau, Tran Thi My Trang, Pham Phu Loc, Bui Minh Cuong, Nguyen The Dung, Ha Vinh, Deborah J Waller, Sir Nicholas White
Transactions of the Royal Society of Tropical Medicine and Hygiene
Sophie Zaloumis, Joel Tärning, Sanjeev Krishna, Ric N. Price, Sir Nicholas White, Timothy M. E. Davis, James M. McCaw, Piero Olliaro, Richard J. Maude, Peter G. Kremsner, Arjen M. Dondorp, Melba Gomes, Karen I. Barnes, J. A. Simpson
Ali Haghiri, David J. Price, Phoebe Fitzpatrick, S Dini, Megha Rajasekhar, Caterina Fanello, Joel Tärning, James A Watson, Sir Nicholas White, J. A. Simpson
Discussion(0)
No comments yet. Be the first to comment.